BridgeBio Pharma Inc 2025年度报告

(Mark One) BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Securities registered pursuant to section 12(g) of the Act:NONE Indicate by check mark if the registrant is a well‑known seasoned issuer, as defined in Rule 405 of the Securities Act. YesNo Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S‑T(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control overfinancial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 726(b)) by the registered public accounting firm that prepared or issued its audit report. If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements. Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Act). YesNo The aggregate market value of the voting and non‑voting common equity held by non‑affiliates of the registrant based upon the closing price of the registrant’s CommonStock on The Nasdaq Global Select Market on June30, 2025 was approximately $7.3 billion. Shares of the registrant’s Common Stock held by each executive officer anddirector and by each other person who may be deemed an affiliate of the Registrant have been excluded from this computation. The determination of affiliate status for thispurpose is not necessarily a conclusive determination for other purposes. On February12, 2026, there were 193,862,871 shares of the registrant’s Common Stock issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the registrant’s definitive Proxy Statement to be issued in conjunction with the registrant’s 2025 Annual Meeting of Stockholders, which isexpected to be filed not later than 120 days after the registrant’s fiscal year ended December31, 2025, are incorporated by reference into Part III of this Annual Report. Exceptas expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10‑K. BRIDGEBIO PHARMA, INC.2025 Form 10‑K Annual Report Table of Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 5.Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities123Item 6.[Reserved]124Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations125Item 7A.Quantitative and Qualitative Disclosures About Market Risk147Item 8.Financial Statements and Supplementary Data148Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure212Item 9A.Controls and Procedures212Item 9B.Other Information214Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections215 PART III PART IV In this Annual Report on Form 10-K, unless otherwise stated or as the context requires, references to “BridgeBio,” “the Company,”“we,” “us,” “our” or similar references refer to BridgeBio Pharma, Inc., together with its consolidated subsidiaries. BRIDGEBIO and ATTRUBY are our registered trademarks in the United States (“U.